Biohaven Ltd. (BHVN) Insider Trading Activity

NYSE$9.55
Market Cap
$1.01B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
17 of 827
Rank in Industry
13 of 469

BHVN Insider Trading Activity

BHVN Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$35,183,395
6
100
Sells
$0
0
0

Related Transactions

CHILDS JOHN Wdirector
3
$27.04M
0
$0
$27.04M
Coric VladChief Executive Officer
1
$5M
0
$0
$5M
Bailey Gregorydirector
1
$3M
0
$0
$3M
Clark George C.VP, Chief Accounting Officer
1
$144,770
0
$0
$144,770

About Biohaven Ltd.

Biohaven Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on development of therapies for neurological and immunoscience diseases that can change current treatment paradigms.

Insider Activity of Biohaven Ltd.

Over the last 12 months, insiders at Biohaven Ltd. have bought $35.18M and sold $0 worth of Biohaven Ltd. stock.

On average, over the past 5 years, insiders at Biohaven Ltd. have bought $29.29M and sold $5.9M worth of stock each year.

Highest buying activity among insiders over the last 12 months: CHILDS JOHN W (director) — $27.04M. Coric Vlad (Chief Executive Officer) — $5M. Bailey Gregory (director) — $3M.

The last purchase of 17,000 shares for transaction amount of $144,770 was made by Clark George C. (VP, Chief Accounting Officer) on 2025‑11‑17.

List of Insider Buy and Sell Transactions, Biohaven Ltd.

2025-11-17PurchaseClark George C.VP, Chief Accounting Officer
17,000
0.0165%
$8.52
$144,770
+9.41%
2025-11-13PurchaseCHILDS JOHN Wdirector
3.33M
2.9193%
$7.50
$25M
+13.01%
2025-11-13PurchaseBailey Gregorydirector
400,000
0.3503%
$7.50
$3M
+13.01%
2025-11-13PurchaseCoric VladChief Executive Officer
666,666
0.5839%
$7.50
$5M
+13.01%
2025-03-04PurchaseCHILDS JOHN Wdirector
32,700
0.0315%
$30.47
$996,238
-50.64%
2024-12-30PurchaseCHILDS JOHN Wdirector
29,000
0.0281%
$35.94
$1.04M
-55.51%
2024-10-02PurchaseCoric VladChief Executive Officer
21,052
0.0215%
$47.50
$999,970
-52.63%
2024-10-02PurchaseCHILDS JOHN Wdirector
21,052
0.0215%
$47.50
$999,970
-52.63%
2024-09-24PurchaseBailey Gregorydirector
5,000
0.0047%
$44.19
$220,966
-38.02%
2024-07-18PurchaseCHILDS JOHN Wdirector
28,400
0.0218%
$35.67
$1.01M
+6.44%
2024-06-17PurchaseCar BruceChief Scientific Officer
30,000
0.0217%
$33.58
$1.01M
+13.11%
2024-05-30PurchaseCHILDS JOHN Wdirector
28,000
0.0214%
$35.58
$996,240
+5.92%
2024-05-13PurchaseCHILDS JOHN Wdirector
28,500
0.0215%
$35.17
$1M
+11.81%
2024-05-13PurchaseBailey Gregorydirector
15,000
0.011%
$34.19
$512,877
+11.81%
2024-04-24PurchaseBailey Gregorydirector
25,503
0.0215%
$39.18
$999,169
-1.32%
2024-04-22PurchaseCoric VladChief Executive Officer
121,951
0.1075%
$41.00
$5M
-0.05%
2024-04-22PurchaseBailey Gregorydirector
48,780
0.043%
$41.00
$2M
-0.05%
2024-04-22PurchaseCHILDS JOHN Wdirector
73,170
0.0645%
$41.00
$3M
-0.05%
2023-12-29SaleAntonijevic Irinadirector
11,000
0.0099%
$41.79
$459,663
-0.12%
2023-10-05PurchaseCHILDS JOHN Wdirector
454,545
0.2149%
$22.00
$10M
+61.12%
Total: 188
*Gray background shows transactions not older than one year

Insider Historical Profitability

19.1%
CHILDS JOHN Wdirector
5653904
5.3407%
$53.99M222
+27.3%
Bailey Gregorydirector
2020071
1.9082%
$19.29M1022
+9.89%
Coric VladChief Executive Officer
1195275
1.1291%
$11.41M98
+10.59%
Clark George C.VP, Chief Accounting Officer
20000
0.0189%
$191,000.0013
Cha Albertdirector
1976818
1.8673%
$18.88M10
Doogan Declandirector
870648
0.8224%
$8.31M031
Buten MatthewChief Financial Officer
189380
0.1789%
$1.81M20
+39.3%
PORTAGE BIOTECH INC.
54494
0.0515%
$520,417.7007
Car BruceChief Scientific Officer
30000
0.0283%
$286,500.0010
+13.11%
GREGORY JULIA Pdirector
25665
0.0242%
$245,100.7513
+17.49%
Engelhart JamesChief Financial Officer
11196
0.0106%
$106,921.8029
Stock ElyseChief Medical Officer
7467
0.0071%
$71,309.8505
Conway CharlesChief Scientific Officer
4000
0.0038%
$38,200.0010
Gentile KimberlySVP, Clinical Operations
3639
0.0034%
$34,752.45011
Antonijevic Irinadirector
2535
0.0024%
$24,209.2501
JONES WILLIAM A JRCCO-Migraine & Common Disease
1755
0.0017%
$16,760.2501
AGUIAR ERICdirector
1250
0.0012%
$11,937.5007
Tilton JohnChief Commercial Officer
770
0.0007%
$7,353.5004
Berman RobertSpecial Projects & Med Ovrsght
341
0.0003%
$3,256.55222
*Gray background shows insiders who have made transactions during last year

Historical Insider Profitability vs. Competitors

$26,838,605
98
5.37%
$966.22M
$61,783,526
37
18.57%
$1.08B
$150,196,329
28
-8.09%
$1.07B
Biohaven Pharmaceutical Holding Company Ltd.
(BHVN)
$103,156,698
27
19.10%
$1.01B
$7,598,498
27
34.68%
$1.03B
$49,750,490
17
37.19%
$1.04B
$26,254,270
14
24.18%
$939.99M
$133,809,976
13
31.29%
$929.13M
$18,336,420
12
24.03%
$1.06B
$11,541,901
10
8.07%
$1.04B
$5,794,001
10
23.26%
$1.02B
$117,959,652
9
-12.47%
$949.13M
$1,580,951
9
-14.18%
$1.08B
$160,798,946
8
-3.92%
$993.02M
$46,235,722
6
-31.77%
$1.01B
$21,792,890
6
75.72%
$975.05M
$19,420,853
5
4.35%
$1.07B
$45,070
4
10.31%
$933.08M
$33,624,000
2
-50.37%
$996.99M

BHVN Institutional Investors: Active Positions

Increased Positions142+52.99%18M+19.92%
Decreased Positions109-40.67%20M-22.48%
New Positions51New2MNew
Sold Out Positions33Sold Out5MSold Out
Total Postitions301+12.31%86M-2.57%

BHVN Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Blackrock, Inc.$78,985.007.43%7.87M+339,618+4.51%2025-09-30
Janus Henderson Group Plc$67,924.006.39%6.77M+2M+34.01%2025-09-30
Stifel Financial Corp$66,312.006.24%6.61M+3,839+0.06%2025-09-30
Suvretta Capital Management, Llc$56,371.005.3%5.62M00%2025-09-30
State Street Corp$42,711.004.02%4.26M+720,120+20.35%2025-09-30
Vanguard Group Inc$28,838.002.71%2.88M-6M-68.92%2025-09-30
Bellevue Group Ag$28,113.002.64%2.8M00%2025-09-30
Fmr Llc$24,342.002.29%2.43M+761,991+45.77%2025-09-30
Geode Capital Management, Llc$20,664.001.94%2.06M+29,289+1.44%2025-09-30
Price T Rowe Associates Inc /Md/$20,156.001.9%2.01M-1M-36.63%2025-09-30

Financial Ratios

Summary
Comparison with Competitors

Price to Earnings

Price/Earnings to Growth

Price to Sales

Price to Book

Price/Free Cash Flow

Analyst Recommendations

Analyst Price Targets

Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.